Pharma BD Deal Intelligence
AbbVie paid $10.1B for ImmunoGen to acquire Elahere, the first ADC approved for FRalpha-positive platinum-resistant ovarian cancer. A bet on biomarker-selected oncology: only ~35% of patients qualify, but for them Elahere offers a differentiated mechanism in a heavily pretreated setting.
AbbVie swooped in to win a bidding war for ImmunoGen, outmaneuvering at least one other suitor. The competitive auction suggests strong market validation of…
Global Elahere net revenues were $690 million for full-year 2025 (an increase of 1.5% reported); Q4 2025 net revenues were $182 million (+22.6% reported).…
Global Elahere net revenues were $198 million in Q1 2026, an increase of 10.7% on a reported basis. Release dated April 29, 2026.
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
AbbVie acquired ImmunoGen for approximately $10.1 billion ($31.26 per share) in an all-cash merger, gaining Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate approved for FRα-positive platinum-resistant ovarian cancer.
Elahere (mirvetuximab soravtansine-gynx) in platinum-sensitive ovarian cancer (PSOC) is an expansion opportunity not currently on-label; the PSOC market is dominated by PARP inhibitors and anti-VEGF agents. PARP inhibitors (PSOC maintenance gold standard): olaparib (Lynparza, AstraZeneca/Merck) per SOLO-2 (BRCA+) and Study 19 (all-comers); niraparib (Zejula, GSK) per NOVA (BRCA+, HRD+, HRD-neg); rucaparib (Rubraca, Pharma&) per ARIEL3 — rucaparib indication was withdrawn in HRD- post-ARIEL4. Anti-VEGF: bevacizumab (Avastin, Roche; biosimilars Mvasi, Zirabev) with platinum-based doublet per OCEANS, GOG-0213, and MITO-16 trials. PARP + anti-VEGF combo: olaparib + bevacizumab maintenance per PAOLA-1 in HRD+ 1L. FRa-targeting ADCs (direct MOA, investigational PSOC): mirvetuximab's PICCOLO single-arm Phase II met ORR in PSOC FRa-high and is the basis for PSOC expansion strategy; rinatabart sesutecan (Rina-S, Genmab) and luveltamab tazevibulin (STRO-002, Sutro) are in PSOC development. Platinum doublet chemotherapy: carboplatin/paclitaxel, carboplatin/gemcitabine, carboplatin/PLD remain the induction backbone. For a commercial lead, Elahere's PSOC threat is gated by PARPi dominance and needs FRa-high enrichment plus platinum-combo PFS advantage to displace PARPi/bevacizumab maintenance.
Elahere (mirvetuximab soravtansine-gynx) in combination development (bevacizumab, PARPi) targets first-line (1L) ovarian cancer maintenance, a setting dominated by established MOA classes. PARP inhibitors (maintenance backbone): olaparib (Lynparza, AstraZeneca/Merck) in BRCA+ 1L maintenance and with bevacizumab per PAOLA-1; niraparib (Zejula, GSK) in biomarker-unselected 1L maintenance per PRIMA; rucaparib (Rubraca, Pharma& — label restricted by ATHENA in HRD+ 1L). Anti-VEGF: bevacizumab (Avastin, Roche; biosimilars Mvasi, Zirabev) in 1L maintenance per GOG-0218 and ICON7 and in combination with PARPi. Anti-PD-1/PD-L1 (mostly failed in 1L): dostarlimab (Jemperli, GSK) and pembrolizumab (Keytruda, Merck) did not meet primary endpoints in 1L ovarian and are limited to dMMR subsets; atezolizumab (Tecentriq) IMagyn050 was negative. FRa-targeting ADCs (direct MOA competitors): rinatabart sesutecan (Rina-S, Genmab/Seagen; TOPO1 payload) is Phase III/II in 1L maintenance combos; luveltamab tazevibulin (Sutro) Phase II/III. For a commercial lead, Elahere's 1L maintenance path (GLORIOSA, MIROVA, PICCOLO) is gated by PARPi/bevacizumab incumbency; differentiation depends on FRa-high enrichment and combo tolerability versus PARPi hematologic toxicity.
Elahere (mirvetuximab soravtansine-gynx) is FDA-approved (full approval March 2024, per MIRASOL) for platinum-resistant ovarian cancer (PROC) with FRa-high tumors — the label it inherits from ImmunoGen. Single-agent chemotherapies (standard comparator): pegylated liposomal doxorubicin (Doxil/Caelyx, J&J; generic), paclitaxel (weekly, generic), topotecan (Hycamtin, generic), and gemcitabine (Gemzar, generic) are the AURELIA-era standards with ~12% ORR and median OS ~12-13 months. Anti-VEGF combinations: bevacizumab (Avastin, Roche; biosimilars) combined with chemo per AURELIA improves PFS over chemo alone. PARP inhibitors (earlier-line, limited PROC role): olaparib (Lynparza), niraparib (Zejula), and rucaparib (Rubraca) are used in PROC off-label in BRCA/HRD populations but have Phase III failures in unselected PROC (ARIEL4). FRa-targeting ADCs (direct MOA competitors): rinatabart sesutecan (Rina-S, Genmab; TOPO1 ADC) Phase III RAINFOL-01, and luveltamab tazevibulin (STRO-002, Sutro) Phase II/III — both directly threaten Elahere's FRa-ADC positioning. For a commercial lead, Elahere's PROC franchise (~$480M reported net sales 2024, per AbbVie 10-K) faces Rina-S competition on the horizon and must defend FRa-high label differentiation.
AbbVie Inc. completed its acquisition of ImmunoGen Inc. for $10.1B. Transaction marks a key portfolio move in Acquisition/Merger strategy.
Traditional approval in FRa+ platinum-resistant ovarian cancer. Regulatory step in AbbVie Inc.'s acquisition process for ImmunoGen Inc..
Elahere met primary endpoint, far exceeding 28% historical ORR for chemo. Part of AbbVie Inc.'s $10.1B deal to acquire ImmunoGen Inc..
AbbVie models $750M for 2025 with $2.8B peak sales projected. Reflects financial performance following AbbVie Inc.'s $10.1B acquisition of ImmunoGen Inc..
AbbVie reported full-year 2025 global Elahere net revenues of $690M (+1.5% reported), below the ~$750M previously modeled, with Q4 2025 re-accelerating to $182M (+22.6%). Q1 2026 reached $198M (+10.7%), supporting the earlier-line expansion thesis.
Scaling to $750M with $2.8B peak. First survival benefit in platinum-resistant ovarian cancer.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / ImmunoGen Inc. (this deal) | 2023 | $10.1B | 69 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
| AbbVie Inc. / MedinCell S.A. | 2024 | $1.9B | 61 |
← Browse all deals · How we score deals
More: 2023 deals · AbbVie Inc. deals · Oncology deals